Taysha Gene Therapies Inc
tayshagtx.comTaysha Gene Therapies (NASDAQ: TSHA) is a clinical-stage gene therapy company developing treatments for rare neurological diseases. It has no approved products and has never generated revenue from product sales as of the 10-K filed March 19, 2026. Operations are funded entirely through equity financings and debt, having raised $961.0 million in gross proceeds from equity financings since inception, including pre-IPO private placements, its IPO, and subsequent public and private securities offerings. The company holds an exclusive, worldwide, royalty-free license from UT Southwestern Medical Center and an exclusive, worldwide, royalty-bearing license from Abeona Therapeutics covering certain gene therapy programs. Net losses were $109.0 million for the year ended December 31, 2025 and $89.3 million for the year ended December 31, 2024, with an accumulated deficit of $711.3 million as of December 31, 2025. All product candidates remain in clinical or preclinical development.
Products & Services
All product candidates are in clinical or preclinical development as of the 10-K filed March 19, 2026. The pipeline is built on gene therapy programs, including programs licensed from UT Southwestern Medical Center and a Rett syndrome program licensed from Abeona Therapeutics. No products are approved for commercialization.
Revenue Model
Taysha generates no product revenue. Operations are financed through equity issuances, at-the-market offerings, and a loan agreement with Trinity Capital. The company previously held a strategic option and securities purchase agreement with Audentes Therapeutics (d/b/a Astellas Gene Therapy).
Customers & Markets
No commercial customers. End markets are patients with rare neurological diseases. Products are in clinical or preclinical development with no approved therapies as of the 10-K filed March 19, 2026.
Geographic Exposure
Incorporated and headquartered in the United States. Licenses are described as worldwide in scope. No commercial geographic revenue mix is disclosed given pre-revenue status.
Financial Snapshot
Loading...
